D-Index & Metrics Best Publications

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 89 Citations 27,247 396 World Ranking 8052 National Ranking 4335

Overview

What is he best known for?

The fields of study he is best known for:

  • Gene
  • Enzyme
  • Internal medicine

Nigel H. Greig mostly deals with Internal medicine, Endocrinology, Neuroscience, Neuroprotection and Alzheimer's disease. His Internal medicine research focuses on Cholinergic in particular. His work deals with themes such as Acetylcholinesterase and Neurotrophin, which intersect with Endocrinology.

His biological study spans a wide range of topics, including Tumor necrosis factor alpha, Neuroinflammation, Pharmacology, Mitochondrion and Traumatic brain injury. His research integrates issues of Dopaminergic, Dopamine, Neurodegeneration and Parkinson's disease in his study of Neuroprotection. The concepts of his Alzheimer's disease study are interwoven with issues in Downregulation and upregulation and Dementia.

His most cited work include:

  • Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent (467 citations)
  • An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript. (434 citations)
  • GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism (413 citations)

What are the main themes of his work throughout his whole career to date?

Nigel H. Greig mainly focuses on Pharmacology, Internal medicine, Endocrinology, Neuroscience and Disease. His Pharmacology research is multidisciplinary, incorporating elements of Acetylcholinesterase and In vivo. His studies deal with areas such as Diabetes mellitus and Oncology as well as Internal medicine.

His Endocrinology research includes themes of Agonist, Receptor and Amyloid beta. In his study, Drug development is strongly linked to Intensive care medicine, which falls under the umbrella field of Disease. His Alzheimer's disease study combines topics in areas such as Immunology and Amyloid.

He most often published in these fields:

  • Pharmacology (26.73%)
  • Internal medicine (24.58%)
  • Endocrinology (21.48%)

What were the highlights of his more recent work (between 2017-2021)?

  • Traumatic brain injury (10.50%)
  • Pharmacology (26.73%)
  • Internal medicine (24.58%)

In recent papers he was focusing on the following fields of study:

His scientific interests lie mostly in Traumatic brain injury, Pharmacology, Internal medicine, Neuroinflammation and Neurodegeneration. Nigel H. Greig has included themes like Inflammation, Excitotoxicity, Programmed cell death, Disease and Neuroscience in his Traumatic brain injury study. Particularly relevant to Neuroprotection is his body of work in Pharmacology.

His research in Internal medicine intersects with topics in Diabetes mellitus, Endocrinology and Oncology. Nigel H. Greig combines subjects such as Prepulse inhibition and Butyrylcholinesterase with his study of Endocrinology. His Neurodegeneration research includes elements of Acetylcholinesterase, Cholinergic, Glucagon-like peptide-1, Microglia and Long-term potentiation.

Between 2017 and 2021, his most popular works were:

  • Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer’s disease (310 citations)
  • Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients with Parkinson Disease: A Secondary Analysis of the Exenatide-PD Trial (69 citations)
  • The Role of microRNAs in Alzheimer's Disease and Their Therapeutic Potentials. (44 citations)

In his most recent research, the most cited papers focused on:

  • Gene
  • Enzyme
  • Internal medicine

Nigel H. Greig mainly investigates Neuroinflammation, Traumatic brain injury, Pharmacology, Neurodegeneration and Neuroscience. He studies Neuroprotection, a branch of Pharmacology. His study on Neurodegeneration is covered under Internal medicine.

The study incorporates disciplines such as Diabetes mellitus and Placebo in addition to Internal medicine. His studies in Neuroscience integrate themes in fields like Parkin, Drug development, Disease and Mitochondrion. His work carried out in the field of Endocrinology brings together such families of science as Long-term potentiation and Genetically modified mouse.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent

Nigel H. Greig;Tadanobu Utsuki;Tadanobu Utsuki;Donald K. Ingram;Yue Wang.
Proceedings of the National Academy of Sciences of the United States of America (2005)

705 Citations

Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer’s disease

E F Fang;Y Hou;K Palikaras;B A Adriaanse.
Nature Neuroscience (2019)

674 Citations

An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript.

Jack T. Rogers;Jeffrey D. Randall;Catherine M. Cahill;Paul S. Eder.
Journal of Biological Chemistry (2002)

602 Citations

GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism

Yazhou Li;Tracy Ann Perry;Mark S. Kindy;Brandon K. Harvey.
Proceedings of the National Academy of Sciences of the United States of America (2009)

569 Citations

A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase.

Nigel H. Greig;Tada Utsuki;Qian-sheng Yu;Xiaoxiang Zhu.
Current Medical Research and Opinion (2001)

477 Citations

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial

Dilan Athauda;Kate Maclagan;Simon S Skene;Martha Bajwa-Joseph.
The Lancet (2017)

476 Citations

Mitophagy and Alzheimer’s Disease: Cellular and Molecular Mechanisms

Jesse S. Kerr;Bryan A. Adriaanse;Nigel H. Greig;Mark P. Mattson;Mark P. Mattson.
Trends in Neurosciences (2017)

430 Citations

Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats.

Margarzata Szayna;Máire E. Doyle;Jennifer A. Betkey;Harold W. Holloway.
Endocrinology (2000)

429 Citations

Butyrylcholinesterase: an important new target in Alzheimer's disease therapy.

Nigel H. Greig;Debomoy K. Lahiri;Kumar Sambamurti.
International Psychogeriatrics (2002)

424 Citations

Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4

TracyAnn Perry;Norman J. Haughey;Mark P. Mattson;Josephine M. Egan.
Journal of Pharmacology and Experimental Therapeutics (2002)

409 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Nigel H. Greig

Mark P. Mattson

Mark P. Mattson

Johns Hopkins University School of Medicine

Publications: 137

Debomoy K. Lahiri

Debomoy K. Lahiri

Indiana University

Publications: 105

Daniel J. Drucker

Daniel J. Drucker

Lunenfeld-Tanenbaum Research Institute

Publications: 52

Ashley I. Bush

Ashley I. Bush

Florey Institute of Neuroscience and Mental Health

Publications: 51

Vilhelm A. Bohr

Vilhelm A. Bohr

National Institutes of Health

Publications: 41

Josephine M. Egan

Josephine M. Egan

National Institutes of Health

Publications: 38

Manuela Bartolini

Manuela Bartolini

University of Bologna

Publications: 37

Jack T. Rogers

Jack T. Rogers

Harvard University

Publications: 36

Stanley I. Rapoport

Stanley I. Rapoport

National Institutes of Health

Publications: 34

Vincenza Andrisano

Vincenza Andrisano

University of Bologna

Publications: 32

Moussa B.H. Youdim

Moussa B.H. Youdim

Technion – Israel Institute of Technology

Publications: 32

Jens J. Holst

Jens J. Holst

University of Copenhagen

Publications: 32

William A. Banks

William A. Banks

University of Washington

Publications: 31

Thomas Foltynie

Thomas Foltynie

University College London

Publications: 30

Chaim G. Pick

Chaim G. Pick

Tel Aviv University

Publications: 29

Donald K. Ingram

Donald K. Ingram

Louisiana State University

Publications: 28

Trending Scientists

Deepak Ganesan

Deepak Ganesan

University of Massachusetts Amherst

Craig L. Pearce

Craig L. Pearce

Pennsylvania State University

Armand Joseph Beaudoin

Armand Joseph Beaudoin

Cornell University

Anuj Batra

Anuj Batra

Apple (United States)

Peter J. Halling

Peter J. Halling

University of Strathclyde

Erich E. Wanker

Erich E. Wanker

Max Delbrück Center for Molecular Medicine

Karen A. Kidd

Karen A. Kidd

McMaster University

Ismael Aranda

Ismael Aranda

Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria

Harikrishna Nakshatri

Harikrishna Nakshatri

Indiana University

Martin J. Humphries

Martin J. Humphries

University of Manchester

Charles A. Stanley

Charles A. Stanley

Children's Hospital of Philadelphia

Patricia A. Duff

Patricia A. Duff

University of British Columbia

Louis N. Pangaro

Louis N. Pangaro

Uniformed Services University of the Health Sciences

Terrence D. Hill

Terrence D. Hill

The University of Texas at San Antonio

Marc F. Plattner

Marc F. Plattner

National Endowment for Democracy

Something went wrong. Please try again later.